0001209191-19-004819.txt : 20190122 0001209191-19-004819.hdr.sgml : 20190122 20190122180425 ACCESSION NUMBER: 0001209191-19-004819 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190117 FILED AS OF DATE: 20190122 DATE AS OF CHANGE: 20190122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wenqing Yao CENTRAL INDEX KEY: 0001624033 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 19536180 MAIL ADDRESS: STREET 1: ROUTE 141 AND HENRY CLAY ROAD CITY: WILMINGTON STATE: DE ZIP: 19880 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-17 0 0000879169 INCYTE CORP INCY 0001624033 Wenqing Yao 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP, Head of Discovery Chem Common Stock 2019-01-17 4 M 0 15354 17.79 A 49763 D Common Stock 2019-01-17 4 S 0 15354 77.61 D 34409 D Non-Qualified Stock Option (right to buy) 17.79 2019-01-17 4 M 0 15354 0.00 D 2019-01-18 Common Stock 15354 0 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Represents weighted average sale price. Actual sale prices ranged from $76.43 to $78.56. Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. This includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. /s/ Michael Purvis, Attorney-In-Fact 2019-01-22